Product Information
OTEZLA 30 MG TABLET is a brand product labeled by Amgen Inc., priced at $90.5717 per EA under NDC 55513013760. Its NADAC has been published 321 times since Aug 12, 2020.
FDA first approved this application on Mar 21, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Amgen Inc.NDC
55513013760
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
APREMILASTApproval Type
New Drug (NDA)
FDA Application
NDA205437FDA Approved
3/21/2014
TE Code
AB
On Market Since
2/26/2020
Pharmacological Classes
Price Statistics
The NADAC for OTEZLA 30 MG TABLET has been published 321 times since Aug 12, 2020, and over the history we have for it it has risen 55.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $90.5717 per EA |
|---|---|
| All-time high | $90.6993 (May 13, 2026) |
| All-time low | $58.0877 (Oct 21, 2020) |
| 52-week high | $90.6993 |
| 52-week low | $86.3686 |
| Median price | $74.4027 |
| Average price | $75.2066 |
| Largest weekly change | +7.4% (Feb 2, 2022) |
| Weeks tracked | 321 |
| Tracking since | Aug 12, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the apremilast market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
apremilast market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OTEZLA 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OTEZLA 30 MG TABLET, manufactured by Amgen Inc., is $90.5717 per EA (NDC 55513013760), effective Sep 30, 2026.
How has the price of OTEZLA 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for OTEZLA 30 MG TABLET has risen 55.6%. It has been tracked across 321 weekly CMS publications since Aug 12, 2020.
What are the highest and lowest recorded NADAC prices for OTEZLA 30 MG TABLET?
Since Aug 12, 2020, the NADAC for OTEZLA 30 MG TABLET has ranged from a low of $58.0877 (Oct 21, 2020) to a high of $90.6993 (May 13, 2026), with a median of $74.4027 per EA.
Are there cheaper alternatives to OTEZLA 30 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of OTEZLA 30 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OTEZLA 30 MG TABLET?
OTEZLA 30 MG TABLET (NDC 55513013760) is labeled by Amgen Inc., and CMS classifies it as a brand product.